Dr. Magda Marquet is a pioneering biotech entrepreneur, investor, and board leader at the forefront of artificial intelligence–driven healthcare innovation. She is the co-founder of Acurion, an AI-powered precision oncology company advancing next-generation approaches to cancer diagnosis and treatment through real-time data intelligence and predictive analytics.
With over three decades of experience building and scaling life sciences companies, Dr. Marquet has consistently translated cutting-edge science into impactful commercial solutions. She previously co-founded Althea Technologies, a leading contract development and manufacturing organization acquired by Ajinomoto, and AltheaDx, a precision medicine company acquired by Castle Biosciences .
At Acurion, she is focused on harnessing AI to enable more precise, personalized, and timely cancer care—bridging the gap between complex biological data and actionable clinical decisions. Her work reflects a broader vision of integrating artificial intelligence into healthcare to improve outcomes and accelerate innovation.
Dr. Marquet is also Co-CEO of ALMA Life Sciences, an investment firm dedicated to advancing transformative healthcare technologies. She serves on the boards of multiple public and private companies, including Arcturus Therapeutics and AnaptysBio, contributing deep expertise in strategy, governance, and company building .
A respected leader in the San Diego life sciences ecosystem, Dr. Marquet holds a Ph.D. in Biochemical Engineering from INSA/University of Toulouse and has received numerous honors, including Ernst & Young Entrepreneur of the Year and Director of the Year .